Trial
NCT03679624
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
Janssen Scientific Affairs, LLC; Mayo Clinic
Condition
Waldenstrom Macroglobulinemia
Intervention
Ibrutinib
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-23